{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:07:54Z","timestamp":1753884474030},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[1999,2,12]],"date-time":"1999-02-12T00:00:00Z","timestamp":918777600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1038\/sj.bjc.6690185","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T14:03:06Z","timestamp":1032271386000},"page":"1162-1167","source":"Crossref","is-referenced-by-count":2,"title":["The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients"],"prefix":"10.1038","volume":"79","author":[{"given":"E","family":"Reyes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Carballido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Alvarez-Mon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[1999,2,12]]},"reference":[{"key":"BF6690185_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","volume":"75","author":"H Akaza","year":"1995","unstructured":"Akaza, H., Hinotsu, S., Aso, Y., Kakizoe, T. & Koiso, K. (1995). Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer, 75: 552\u2013559.","journal-title":"Cancer"},{"key":"BF6690185_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/00365516809076979","volume":"21","author":"AJ Boyum","year":"1968","unstructured":"Boyum, A. J. (1968). Isolation of mononuclear cells and granulocytes from human blood. Scan J Clin Lab Invest, 21: 77\u201379.","journal-title":"Scan J Clin Lab Invest"},{"key":"BF6690185_CR3","first-page":"149","volume":"43","author":"J Carballido","year":"1990","unstructured":"Carballido, J., Alvarez Mon, M., Olivier, C. & Molto, L. (1990a). Immunotherapy of urothelial neoplasms. Experimental and clinical implications of alpha interferon. Arch Esp Urol, 43: 149\u2013158.","journal-title":"Arch Esp Urol"},{"key":"BF6690185_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0022-5347(17)39854-3","volume":"143","author":"J Carballido","year":"1990","unstructured":"Carballido, J., Alvarez Mon, M., Solovera, O. J., Menendez Ondina, L. & Durantez, A. (1990b). Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. J Urol, 143: 29\u201333.","journal-title":"J Urol"},{"key":"BF6690185_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","volume":"155","author":"TM De Reijke","year":"1996","unstructured":"De Reijke, T. M., De Boer, E. C., Kurth, K. H. & Schamhart, D. H. (1996). Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol, 155: 477\u2013482.","journal-title":"J Urol"},{"key":"BF6690185_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF02550135","volume":"28","author":"M Erton","year":"1996","unstructured":"Erton, M. & Ilker, Y. Akdas (1996). Carcinoma in situ and treatment options. Int Urol Nephrol 28: 33\u201342.","journal-title":"Int Urol Nephrol"},{"key":"BF6690185_CR7","first-page":"154","volume":"15","author":"D Esrig","year":"1997","unstructured":"Esrig, D., Freeman, J., Stein, J. & Skinner, D. (1997). Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol, 15: 154\u2013160.","journal-title":"Semin Urol Oncol"},{"key":"BF6690185_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/BF00917476","volume":"10","author":"GG Hermann","year":"1990","unstructured":"Hermann, G. G., Petersen, K. R., Steven, K. & Zeuthen, J. (1990). Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol, 10: 311\u2013320.","journal-title":"J Clin Immunol"},{"key":"BF6690185_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S0022-5347(01)65458-2","volume":"156","author":"R Hurle","year":"1996","unstructured":"Hurle, R., Losa, A., Ranieri, A., Graziotti, P. & Lembo, A. (1996). Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol, 156: 1602\u20131605.","journal-title":"J Urol"},{"key":"BF6690185_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jcp.47.4.309","volume":"47","author":"AM Jackson","year":"1994","unstructured":"Jackson, A. M., Alexandroff, A. B., McIntyre, M., Esuvaranathan, K., James, K. & Chisholm, G. D. (1994). Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol, 47: 309\u2013312.","journal-title":"J Clin Pathol"},{"key":"BF6690185_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"AM Jackson","year":"1995","unstructured":"Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S., Chisholm, G. D. & James, K. (1995). Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol, 99: 369\u2013375.","journal-title":"Clin Exp Immunol"},{"key":"BF6690185_CR12","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","volume":"14","author":"R Kaempfer","year":"1996","unstructured":"Kaempfer, R., Gerez, L., Farbstein, H., Madar, L., Hirschman, O., Nussinovich, R. & Shapiro, A. (1996). Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol, 14: 1778\u20131786.","journal-title":"J Clin Oncol"},{"key":"BF6690185_CR13","volume-title":"Atlas of Tumour Pathology","author":"LM Koss","year":"1973","unstructured":"Koss, L. M. (1973). Tumours of the urinary bladder. In Atlas of Tumour Pathology, Armed Forces Institute of Pathology(eds) pp ???"},{"key":"BF6690185_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000474526","volume":"31","author":"K Kurth","year":"1997","unstructured":"Kurth, K. (1997). Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives. Eur Urol, 31: 10\u201319.","journal-title":"Eur Urol"},{"key":"BF6690185_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0022-5347(01)64484-7","volume":"158","author":"K Kurth","year":"1997","unstructured":"Kurth, K., Tunn, U., Ay, R., Schroder, F., Pavone-Macaluso, M., Debruyne, F., ten Kate, F., de Pauw, M. & Sylvester, R. (1997). Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158: 378\u2013384.","journal-title":"J Urol"},{"key":"BF6690185_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/canjclin.46.2.93","volume":"46","author":"DL Lamm","year":"1996","unstructured":"Lamm, D. L. & Torti, F. M. (1996). Bladder cancer, 1996. CA Cancer J Clin, 46: 93\u2013112.","journal-title":"CA Cancer J Clin"},{"key":"BF6690185_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/(SICI)1098-2388(199709\/10)13:5<307::AID-SSU4>3.0.CO;2-H","volume":"13","author":"R Lapham","year":"1997","unstructured":"Lapham, R., Ro, J., Staerkel, G. & Ayala, A. (1997). Pathology of transitional cell carcinoma of the bladder and its clinical implications. Semin Surg Oncol, 13: 307\u2013318.","journal-title":"Semin Surg Oncol"},{"key":"BF6690185_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/283664a0","volume":"283","author":"EL Larson","year":"1980","unstructured":"Larson, E. L., Iscove, N. N. & Coutinho, A. (1980). Two distinct factors are required for induction of T-cell growth. Nature, 283: 664\u2013666.","journal-title":"Nature"},{"key":"BF6690185_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0090-4295(99)80115-0","volume":"45","author":"D Mack","year":"1995","unstructured":"Mack, D. & Frick, J. (1995). Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology, 45: 958\u2013961.","journal-title":"Urology"},{"key":"BF6690185_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0022-1759(80)90003-4","volume":"33","author":"M Madsen","year":"1980","unstructured":"Madsen, M., Johnsen, H. E., Hansen, P. W. & Christiansen, S. E. (1980). Isolation of human T and B lymphocytes by E-rosette gradient centrifugation. Characterization of the isolated sub-populations. J Immunol Methods, 33: 323\u2013336.","journal-title":"J Immunol Methods"},{"key":"BF6690185_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-3083.1995.tb03533.x","volume":"41","author":"H Maes","year":"1995","unstructured":"Maes, H., Taper, H. & Cocito, C. (1995). Alteration of the immune response during cancer development and prevention by administration of a mycobacterial antigen. Scand J Immunol 41: 53\u201364.","journal-title":"Scand J Immunol"},{"key":"BF6690185_CR22","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/1097-0142(19950601)75:11<2720::AID-CNCR2820751114>3.0.CO;2-4","volume":"75","author":"L Molto","year":"1995","unstructured":"Molto, L., Alvarez-Mon, M., Carballido, J., Olivier, C., Gimeno, F. & Manzano, L. (1995). Use of intracavitary interferon alpha 2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer 75: 1720\u20132726.","journal-title":"Cancer"},{"key":"BF6690185_CR23","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/bjc.1997.315","volume":"75","author":"L Molto","year":"1997","unstructured":"Molto, L., Carballido, J., Manzano, L., Reyes, E., Olivier, C. & Alvarez-Mon, M. (1997). Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Br J Cancer, 75: 1849\u20131853.","journal-title":"Br J Cancer"},{"key":"BF6690185_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","volume":"152","author":"RB Nadler","year":"1994","unstructured":"Nadler, R. B., Catalona, W. J., Hudson, M. A. & Ratliff, T. L. (1994). Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol, 152: 367\u2013373.","journal-title":"J Urol"},{"key":"BF6690185_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0022-1759(90)90159-S","volume":"126","author":"M Nicks","year":"1990","unstructured":"Nicks, M., Otto, M., Busova, B. & Stefanovic, J. (1990). Quantification of proliferative and suppressive responses of human T lymphocytes following ConA stimulation. J Immunol Methods 126: 263\u2013271.","journal-title":"J Immunol Methods"},{"key":"BF6690185_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1055-3207(18)30447-2","volume":"4","author":"MA O\u2019Donnell","year":"1995","unstructured":"O\u2019Donnell, M. A. & DeWolf, W. C. (1995). Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am, 4: 189\u2013202.","journal-title":"Surg Oncol Clin N Am"},{"key":"BF6690185_CR27","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/S0022-5347(01)66692-8","volume":"154","author":"V Pansadoro","year":"1995","unstructured":"Pansadoro, V., Emiliozzi, P., Defidio, L., Donadio, D., Florio, A., Maurelli, S., Lauretti, S. & Sternberg, C. N. (1995). Bacillus Calmette\u2013Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol, 154: 2054\u20132058.","journal-title":"J Urol"},{"key":"BF6690185_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF00211413","volume":"11","author":"JJ Patard","year":"1993","unstructured":"Patard, J. J., Chopin, D. K. & Boccon Gibod, L. (1993). Mechanisms of action of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. World J Urol 11: 165\u2013168.","journal-title":"World J Urol"},{"key":"BF6690185_CR29","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.4049\/jimmunol.145.10.3247","volume":"145","author":"LJ Picker","year":"1990","unstructured":"Picker, L. J., Terstappen, LWMM, Rott, L. S., Streeter, P. R., Stein, H. & Butcher, E. C. (1990). Differential expression of homing-associated adhesion molecules by T cell subsets in man. J Immunol, 145: 3247\u20133255.","journal-title":"J Immunol"},{"key":"BF6690185_CR30","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. & Smyth, J. F. (1992). Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147: 1636\u20131642.","journal-title":"J Urol"},{"key":"BF6690185_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/bjc.1995.155","volume":"71","author":"K Pryor","year":"1995","unstructured":"Pryor, K., Goddard, J., Goldstein, D., Stricker, P., Russell, P., Golovsky, D. & Penny, R. (1995). Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer, 71: 801\u2013807.","journal-title":"Br J Cancer"},{"key":"BF6690185_CR32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. & Catalona, W. J. (1993). T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol, 150: 1018\u20131023.","journal-title":"J Urol"},{"key":"BF6690185_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0090-4295(99)80418-X","volume":"47","author":"RS Rosenbaum","year":"1996","unstructured":"Rosenbaum, R. S., Park, M. C. & Fleischmann, J. (1996). Intravesical bacille Calmette-Guerin therapy for muscle invasive bladder cancer. Urology, 47: 208\u2013211.","journal-title":"Urology"},{"key":"BF6690185_CR34","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.4049\/jimmunol.157.9.3886","volume":"157","author":"M Satoh","year":"1996","unstructured":"Satoh, M., Seki, S., Hashimoto, W., Ogasawara, K., Kobayashi, T., Kumagai, K., Matsuno, S. & Takeda, K. (1996). Citotoxic \u03b3\u03b4 or \u03b1\u03b2 T cells with a Natural Killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol, 157: 3886\u20133892.","journal-title":"J Immunol"},{"key":"BF6690185_CR35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/BF02552138","volume":"27","author":"M Takashi","year":"1995","unstructured":"Takashi, M., Wakai, K., Ohno, Y., Murase, T. & Miyake, K. (1995). Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol, 27: 723\u2013733.","journal-title":"Int Urol Nephrol"},{"key":"BF6690185_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF01520291","volume":"40","author":"A Thanhauser","year":"1995","unstructured":"Thanhauser, A., Bohle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M., Flad, H. D. & Ulmer, A. J. (1995). The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother, 40: 103\u2013108.","journal-title":"Cancer Immunol Immunother"},{"key":"BF6690185_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.1365-2567.1996.512590.x","volume":"87","author":"J Turner","year":"1996","unstructured":"Turner, J. & Dockrell, H. M. (1996). Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology, 87: 339\u2013342.","journal-title":"Immunology"},{"key":"BF6690185_CR38","first-page":"325","volume":"9","author":"A Verhagen","year":"1990","unstructured":"Verhagen, A., Mackay, I. R., Rowley, M. & Tymms, M. (1990). Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul, 9: 325\u2013333.","journal-title":"Nat Immun Cell Growth Regul"},{"key":"BF6690185_CR39","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.4049\/jimmunol.155.7.3443","volume":"155","author":"PR Walker","year":"1995","unstructured":"Walker, P. R., Ohteki, T., Lopez, J. A., MacDonald, H. R. & Maryanski, J. L. (1995). Distinct phenotypes of antigen-selected CD8 T cells emerge at different stages of an in vivo immune response. J Immunol, 155: 3443\u20133452.","journal-title":"J Immunol"},{"key":"BF6690185_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003495-199753030-00005","volume":"53","author":"J Witjes","year":"1997","unstructured":"Witjes, J. (1997). Current recommendations for the management of bladder cancer. Drug therapy. Drugs, 53: 404\u2013414.","journal-title":"Drugs"},{"key":"BF6690185_CR41","first-page":"63","volume":"62","author":"A Zlotta","year":"1994","unstructured":"Zlotta, A., Drowart, A., van Vooren, J. P., Simon, J., Schulman, C. C. & Huygen, K. (1994). Evolution of cellular and humoral response against tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer. Acta Urol Belg, 62: 63\u201368.","journal-title":"Acta Urol Belg"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6690185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690185","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:51:04Z","timestamp":1684414264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6690185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2,12]]},"references-count":41,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["BF6690185"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6690185","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2,12]]}}}